Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Neuropharmacology
  4. Volume 23, Issue 7
  5. Article
Volume 23, Issue 7
  • ISSN: 1570-159X
  • E-ISSN: 1875-6190

Abstract

Background

The study demonstrates that pharmacological blockade of type 3 metabotropic glutamate (mGlu3) receptors at the time of tumor induction significantly reduces the incidence of brain gliomas in rats. The overall survival of patients with high-grade brain gliomas is 14-20 months after current multimodal therapy, including surgery, radiotherapy, and adjuvant chemotherapy.

Objective

To demonstrate in this experimental model that pharmacological blockade of group II metabotropic glutamate receptors reduces the incidence of brain tumors induced by prenatal exposure to N- ethyl-N-nitrosourea (ENU) in rats.

Methods

Dams received a single injection of ENU (40 mg/kg, e.v.) at day 20 of pregnancy, combined with 5 daily injections of either saline or the mGlu2/3 receptor antagonist, LY341495 (10 mg/kg) (from day 15 to day 21 of pregnancy). Assessment of brain tumors in the offspring at 5 months of age showed the presence of mixed gliomas (astrocytomas/oligodendrogliomas) in 70% of the ENU + saline group of rats and only in 30% of the ENU + LY341495 group.

Conclusion

Tumors in both groups of rats showed a moderate/high expression of the astrocyte marker, GFAP, and the oligodendrocyte marker, OLIG-2, and a low expression of the proliferation marker, Ki-67. However, tumors of the ENU + LY341495 group showed a reduced density of Iba-1+ cells, suggesting a lower extent of neuroinflammation in the tumor microenvironment. These findings strengthen the hypothesis that mGlu3 receptors are candidate drug targets for the treatment of malignant gliomas.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cn/10.2174/1570159X23666241209090326
2024-12-10
2025-06-13

  • From This Site

    /content/journals/cn/10.2174/1570159X23666241209090326
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ArcellaA. CarpinelliG. BattagliaG. D’OnofrioM. SantoroF. NgombaR.T. BrunoV. CasoliniP. GiangasperoF. NicolettiF. Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo.Neuro-oncol.20057323624510.1215/S1152851704000961 16053698
     [Google Scholar]
  2. NicolettiF. ArcellaA. IacovelliL. BattagliaG. GiangasperoF. MelchiorriD. Metabotropic glutamate receptors: New targets for the control of tumor growth?Trends Pharmacol. Sci.200728520621310.1016/j.tips.2007.03.008 17433452
     [Google Scholar]
  3. CiceroniC. ArcellaA. MosilloP. BattagliaG. MastrantoniE. OlivaM.A. CarpinelliG. SantoroF. SaleP. Ricci-VitianiL. De MariaR. PalliniR. GiangasperoF. NicolettiF. MelchiorriD. Type-3 metabotropic glutamate receptors negatively modulate bone morphogenetic protein receptor signaling and support the tumourigenic potential of glioma-initiating cells.Neuropharmacology200855456857610.1016/j.neuropharm.2008.06.064 18621067
     [Google Scholar]
  4. CiceroniC. BonelliM. MastrantoniE. NiccoliniC. LaurenzaM. LaroccaL.M. PalliniR. TraficanteA. SpinsantiP. Ricci-VitianiL. ArcellaA. De MariaR. NicolettiF. BattagliaG. MelchiorriD. Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas.Cell Death Differ.201320339640710.1038/cdd.2012.150 23175182
     [Google Scholar]
  5. StefaniM.A. ModkovskiR. HanselG. ZimmerE.R. KopczynskiA. MullerA.P. StrogulskiN.R. RodolphiM.S. CarteriR.K. SchmidtA.P. OsesJ.P. SmithD.H. PortelaL.V. Elevated glutamate and lactate predict brain death after severe head trauma.Ann. Clin. Transl. Neurol.20174639240210.1002/acn3.416 28589166
     [Google Scholar]
  6. WirschingH.G. SilginerM. VenturaE. MacnairW. BurghardtI. ClaassenM. GattiS. WichmannJ. RiemerC. SchneiderH. WellerM. Negative allosteric modulators of metabotropic glutamate receptor 3 target the stem-like phenotype of glioblastoma.Mol. Ther. Oncolytics20212016617410.1016/j.omto.2020.12.009 33575479
     [Google Scholar]
  7. MaierJ.P. RaviV.M. KueckelhausJ. BehringerS.P. GarrelfsN. WillP. SunN. von EhrJ. GoeldnerJ.M. PfeiferD. FolloM. HannibalL. WalchA.K. HofmannU.G. BeckJ. HeilandD.H. SchnellO. JosephK. Inhibition of metabotropic glutamate receptor III facilitates sensitization to alkylating chemotherapeutics in glioblastoma.Cell Death Dis.202112872310.1038/s41419‑021‑03937‑9 34290229
     [Google Scholar]
  8. TanabeY. MasuM. IshiiT. ShigemotoR. NakanishiS. A family of metabotropic glutamate receptors.Neuron19928116917910.1016/0896‑6273(92)90118‑W 1309649
     [Google Scholar]
  9. CondorelliD.F. Dell’AlbaniP. CorsaroM. GiuffridaR. CarusoA. A, T.S.; Spinella, F.; Nicoletti, F.; Albanese, V.; Stella, A.M.G. Metabotropic glutamate receptor expression in cultured rat astrocytes and human gliomas.Neurochem. Res.19972291127113310.1023/A:1027317319166 9251103
     [Google Scholar]
  10. NicolettiF. BockaertJ. CollingridgeG.L. ConnP.J. FerragutiF. SchoeppD.D. WroblewskiJ.T. PinJ.P. Metabotropic glutamate receptors: From the workbench to the bedside.Neuropharmacology2011607-81017104110.1016/j.neuropharm.2010.10.022 21036182
     [Google Scholar]
  11. Di MennaL. JoffeM.E. IacovelliL. OrlandoR. LindsleyC.W. MairesseJ. GressènsP. CannellaM. CaraciF. CopaniA. BrunoV. BattagliaG. ConnP.J. NicolettiF. Functional partnership between mGlu3 and mGlu5 metabotropic glutamate receptors in the central nervous system.Neuropharmacology201812830131310.1016/j.neuropharm.2017.10.026 29079293
     [Google Scholar]
  12. JoffeM.E. SantiagoC.I. StansleyB.J. MaksymetzJ. GogliottiR.G. EngersJ.L. NicolettiF. LindsleyC.W. ConnP.J. Mechanisms underlying prelimbic prefrontal cortex mGlu3/mGlu5-dependent plasticity and reversal learning deficits following acute stress.Neuropharmacology2019144192810.1016/j.neuropharm.2018.10.013 30326237
     [Google Scholar]
  13. DograS. StansleyB.J. XiangZ. QianW. GogliottiR.G. NicolettiF. LindsleyC.W. NiswenderC.M. JoffeM.E. ConnP.J. Activating mGlu3 Metabotropic glutamate receptors rescues schizophrenia-like cognitive deficits through metaplastic adaptations within the hippocampus.Biol. Psychiatry202190638539810.1016/j.biopsych.2021.02.970 33965197
     [Google Scholar]
  14. D’OnofrioM. ArcellaA. BrunoV. NgombaR.T. BattagliaG. LombariV. RagonaG. CalogeroA. NicolettiF. Pharmacological blockade of mGlu2/3 metabotropic glutamate receptors reduces cell proliferation in cultured human glioma cells.J. Neurochem.20038461288129510.1046/j.1471‑4159.2003.01633.x 12614329
     [Google Scholar]
  15. GersonS.L. MGMT: Its role in cancer aetiology and cancer therapeutics.Nat. Rev. Cancer20044429630710.1038/nrc1319 15057289
     [Google Scholar]
  16. DenlingerR.H. KoestnerA. WechslerW. Induction of neurogenic tumors in C3HeB/FeJ mice by nitrosourea derivatives: Observations by light microscopy, tissue culture, and electron microscopy.Int. J. Cancer197413455957110.1002/ijc.2910130416 4366972
     [Google Scholar]
  17. WechslerW. KoestnerA. Developmental biology related to oncology. Pririciples of Sirrgical Oticology. RavenR.W. London, New YorkPlenum Publishing Corporation19779310810.1007/978‑1‑4684‑2301‑3_6
     [Google Scholar]
  18. KoestnerA. Characterization of N-nitrosourea-induced tumors of the nervous system; their prospective value for studies of neurocarcinogenesis and brain tumor therapy.Toxicol. Pathol.1990181_part_218619210.1177/019262339001800124 2195638
     [Google Scholar]
  19. DruckreyH. IvankovićS. PreussmannR. Teratogenic and carcinogenic effects in the offspring after single injection of ethylnitrosourea to pregnant rats.Nature196621050431378137910.1038/2101378a0 6007120
     [Google Scholar]
  20. Cruz-OriveL.M. Stereology of single objects.J. Microsc.199718629310710.1046/j.1365‑2818.1997.1380695.x
     [Google Scholar]
  21. LierJ. StreitW.J. BechmannI. Beyond activation: Characterizing microglial functional phenotypes.Cells2021109223610.3390/cells10092236 34571885
     [Google Scholar]
  22. BasheerA.S. AbasF. OthmanI. NaiduR. Role of inflammatory mediators, macrophages, and neutrophils in glioma maintenance and progression: Mechanistic understanding and potential therapeutic applications.Cancers (Basel)20211316422610.3390/cancers13164226 34439380
     [Google Scholar]
  23. YeungY.T. BryceN.S. AdamsS. BraidyN. KonayagiM. McDonaldK.L. TeoC. GuilleminG.J. GrewalT. MunozL. p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and the invasiveness of human U251 glioblastoma cells.J. Neurooncol.20121091354410.1007/s11060‑012‑0875‑7 22528800
     [Google Scholar]
  24. CaridiM. AlborghettiM. PellicelliV. OrlandoR. PontieriF.E. BattagliaG. ArcellaA. Metabotropic glutamate receptors type 3 and 5 feature the “neurotransmitter-type” of glioblastoma: A bioinformatic approach.Curr. Neuropharmacol.202422111923193910.2174/1570159X22666240320112926 38509672
     [Google Scholar]
/content/journals/cn/10.2174/1570159X23666241209090326
Loading
Pharmacological Blockade of Group II Metabotropic Glutamate Receptors Reduces the Incidence of Brain Tumors Induced by Prenatal Exposure to N-ethyl-N-nitrosourea in Rats
Curr. Neuropharmacol. 23, 872 (2025); https://doi.org/10.2174/1570159X23666241209090326
/content/journals/cn/10.2174/1570159X23666241209090326
/content/journals/cn/10.2174/1570159X23666241209090326
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): brain tumors; Glioblastoma multiforme; glutamate; metabotropic glutamate receptors; N-ethyl-N-nitrosourea; rats

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test